JP7476219B2 - Cd137およびgpc3に特異的な新規融合タンパク質 - Google Patents

Cd137およびgpc3に特異的な新規融合タンパク質 Download PDF

Info

Publication number
JP7476219B2
JP7476219B2 JP2021549919A JP2021549919A JP7476219B2 JP 7476219 B2 JP7476219 B2 JP 7476219B2 JP 2021549919 A JP2021549919 A JP 2021549919A JP 2021549919 A JP2021549919 A JP 2021549919A JP 7476219 B2 JP7476219 B2 JP 7476219B2
Authority
JP
Japan
Prior art keywords
seq
gpc3
fusion protein
fusion proteins
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523524A (ja
JP2022523524A5 (cg-RX-API-DMAC7.html
Inventor
アイバ ラシダ シハム ベル
ビルギット ボッセンマイアー
トーマス ジャキン
ジャネット ペパー-ガブリエル
エバ-マリア ハンスバウアー
コリンナ シュロッサー
シェーン オルヴィル
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2022523524A publication Critical patent/JP2022523524A/ja
Publication of JP2022523524A5 publication Critical patent/JP2022523524A5/ja
Application granted granted Critical
Publication of JP7476219B2 publication Critical patent/JP7476219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021549919A 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質 Active JP7476219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19000100.8 2019-02-26
EP19000100 2019-02-26
PCT/EP2020/054821 WO2020173897A1 (en) 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3

Publications (3)

Publication Number Publication Date
JP2022523524A JP2022523524A (ja) 2022-04-25
JP2022523524A5 JP2022523524A5 (cg-RX-API-DMAC7.html) 2022-12-13
JP7476219B2 true JP7476219B2 (ja) 2024-04-30

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549919A Active JP7476219B2 (ja) 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質

Country Status (13)

Country Link
US (1) US12486330B2 (cg-RX-API-DMAC7.html)
EP (1) EP3931209A1 (cg-RX-API-DMAC7.html)
JP (1) JP7476219B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474359B (cg-RX-API-DMAC7.html)
AU (1) AU2020229436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016829A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124441A1 (cg-RX-API-DMAC7.html)
IL (1) IL284687B2 (cg-RX-API-DMAC7.html)
MA (1) MA55069A (cg-RX-API-DMAC7.html)
MX (1) MX2021010039A (cg-RX-API-DMAC7.html)
SG (1) SG11202106353VA (cg-RX-API-DMAC7.html)
WO (1) WO2020173897A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104287B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
IL307466A (en) * 2021-04-05 2023-12-01 Cytovia Therapeutics Llc Bispecific antibodies targeting nkp46 and gpc3 and methods of use thereof
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
WO2022242682A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
WO2023016564A1 (zh) * 2021-08-12 2023-02-16 上海才致药成生物科技有限公司 靶向GPC3的抗体干扰素α融合蛋白及其用途
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN113912699A (zh) * 2021-10-14 2022-01-11 江南大学 一种新型治疗乳腺癌的fgf类似物及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
US20250195681A1 (en) * 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
CN122255279A (zh) * 2022-11-21 2026-06-23 广州百济神州生物制药有限公司 抗cd137抗体和使用方法
CN119613552B (zh) * 2024-07-23 2025-11-28 艾可泰科(浙江)控股有限公司 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035584A1 (en) 2003-10-10 2005-04-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
JP2009545301A (ja) 2006-08-01 2009-12-24 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
JP2013544756A (ja) 2010-09-09 2013-12-19 ファイザー・インク 4−1bb結合分子
WO2016047722A1 (ja) 2014-09-26 2016-03-31 中外製薬株式会社 細胞傷害誘導治療剤
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
JP2018515085A (ja) 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
JP2018515084A (ja) 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー Cd137に特異的なタンパク質
JP2018519802A (ja) 2015-05-18 2018-07-26 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン
JP2018519803A (ja) 2015-05-18 2018-07-26 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん性融合ポリペプチド
WO2018228442A1 (en) 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ.ホフマン−ラ ロシュ アーゲー 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035584A1 (en) 2003-10-10 2005-04-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
JP2009545301A (ja) 2006-08-01 2009-12-24 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
JP2013544756A (ja) 2010-09-09 2013-12-19 ファイザー・インク 4−1bb結合分子
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2016047722A1 (ja) 2014-09-26 2016-03-31 中外製薬株式会社 細胞傷害誘導治療剤
JP2018515085A (ja) 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
JP2018515084A (ja) 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー Cd137に特異的なタンパク質
JP2018519802A (ja) 2015-05-18 2018-07-26 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン
JP2018519803A (ja) 2015-05-18 2018-07-26 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん性融合ポリペプチド
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2018228442A1 (en) 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof

Also Published As

Publication number Publication date
JP2022523524A (ja) 2022-04-25
WO2020173897A1 (en) 2020-09-03
EP3931209A1 (en) 2022-01-05
US20220153864A1 (en) 2022-05-19
KR20210133254A (ko) 2021-11-05
IL284687B2 (en) 2025-11-01
SG11202106353VA (en) 2021-07-29
ZA202104287B (en) 2026-03-25
BR112021016829A2 (pt) 2021-10-19
IL284687A (en) 2021-08-31
AU2020229436A1 (en) 2021-07-01
US12486330B2 (en) 2025-12-02
IL284687B1 (en) 2025-07-01
MX2021010039A (es) 2021-09-21
CN113474359B (zh) 2025-02-21
CA3124441A1 (en) 2020-09-03
CN113474359A (zh) 2021-10-01
MA55069A (fr) 2022-01-05
AU2020229436B2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
JP7482488B2 (ja) Cd137とpd-l1に特異的な新規融合タンパク質
US12486330B2 (en) Fusion proteins specific for CD137 and GPC3
RU2754466C2 (ru) Слитый полипептид с противораковой активностью
EP3292148A1 (en) Anti-cancer fusion polypeptide
JP2025532652A (ja) Cd137およびcd228に特異的な新規融合タンパク質
RU2814653C2 (ru) Новые слитые белки, специфические в отношении cd137 и gpc3
RU2818349C2 (ru) Новый слитый белок, специфичный для cd137 и pd-l1
EA046634B1 (ru) Новый слитый белок, специфичный к cd137 и pd-l1
WO2023089079A1 (en) Novel fusion protein specific for ox40 and pd-l1
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273B (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273A (en) Novel fusion protein specific for cd137 and pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240417

R150 Certificate of patent or registration of utility model

Ref document number: 7476219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150